Key Highlights

  • Braveheart Bio closed down 11.77% at $20.62, extending a decline that has cut sharply from the stock this year.
  • Short interest reached 33% of shares outstanding, with 7.5 days needed to cover average volume.
  • The stock holds $122.83 million in cash and equivalents with a Debt-to-Equity Ratio of 0.00, despite analyst assessments ranging from Moderate Buy to Strong Buy.

Braveheart Bio (NASDAQ:BRVE) closed down 11.77% at $20.62, extending a decline that has cut sharply from the stock this year. The move contrasts with analyst assessments ranging from Moderate Buy to Strong Buy, while thin trading Volume and elevated short interest add uncertainty around the selloff's durability for investors.

BRVE Trading Context Shows a Thin Down Session

Braveheart Bio's Market Value was listed at about $2.1 billion, placing the move in the context of a sizable publicly traded pharmaceutical name rather than a microcap security. Shares were down sharply over the past month and year-to-date before the latest decline was incorporated into the broader performance picture. Trading activity remained light relative to the full-day norm, which limits how much conviction can be assigned to the move from turnover alone.

RSI Leaves BRVE Near First Support

BRVE traded below its 20-day Moving Average of $26.22. The 14-day RSI was 35.2, a weak reading that remained above the conventional oversold boundary. MACD was negative at -1.15 and sat below its -0.47 signal line. ADX measured 22.5. The first nearby support level was $19.57, while resistance appeared at $22.54 and then $30.23.

Pharmaceuticals Classification Frames Braveheart Bio

Braveheart Bio is classified in the Pharmaceuticals: Major industry group. The company had 7,535,986 shares outstanding. Cash and equivalents stood at $122.83 million, with a debt-to-equity ratio of 0.00. Short interest reached 33% of shares outstanding, with 7.5 days to cover and the position up 76% from the prior settlement.